Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis
Abstract
Joint senior authors. Joint senior authors. Hum. Reprod Update. 2015;21:560–574 The authors would like to apologise for an error in the specific meta-analysis examining the effect of 6 months of lifestyle + metformin treatment vs lifestyle ± placebo treatment in patients with polycystic ovary syndrome (PCOS). This error arose as a result of inaccurate data transfer from a single extraction table of data from Karimzadeh and Javedani (Karimzadeh and Javedani, 2010) and Ladson studies (Ladson et al., 2011a, b) to RevMan analysis software. With limited BMI data at 6 months comparing these two groups, data was obtained from original manuscripts and directly from contacted authors and a new meta-analysis has been performed for change in BMI over 6 months, showing a greater, though not statistically significant reduction in BMI with lifestyle + metformin vs lifestyle ± placebo (95%CI: -0.85, 0.01, p = 0.06) (Figure 3). In the text below we have described the amendments. In the Results section of the abstract (page 561): “Lifestyle and metformin were associated with lower BMI (mean difference (MD) -0.73 kg/m2, 95% confidence intervals (CI) -1.14, -0.32, P = 0.0005) and subcutaneous adipose tissue (MD -92.49cm2, 95% CI -164.14, -20.84, P = 0.01) and increased number of menstrual cycles (MD 1.06, 95% CI 0.30, 1.82, P = 0.006) after 6 months compared with lifestyle ± placebo.” should be corrected to “Lifestyle and metformin was associated with a greater BMI reduction over 6 months…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 608 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.